U.S. patent application number 13/345570 was filed with the patent office on 2012-12-06 for methods and use of inducing apoptosis in cancer cells.
This patent application is currently assigned to Cytotech Labs, LLC. Invention is credited to John Patrick McCook, Niven Rajin Narain, Indushekhar Persaud.
Application Number | 20120309086 13/345570 |
Document ID | / |
Family ID | 41162239 |
Filed Date | 2012-12-06 |
United States Patent
Application |
20120309086 |
Kind Code |
A1 |
Narain; Niven Rajin ; et
al. |
December 6, 2012 |
METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS
Abstract
The present disclosure relates to a method of inducing apoptosis
in a cancer cell by delivery of exogenous Coenzyme Q10 or its
metabolites thereof in a pharmaceutically acceptable carrier to
effectuate cell contact of endogenous Coenzyme Q10 or its
metabolites thereof in addition to but not limited to mevalonic
acid and oleic acid to form an intracellular complex. The present
disclosure also provides a method of modulating the p53 pathway and
Bcl-2 protein family in a manner that restores the apoptotic
potential to a cancer cell by delivery of Coenzyme Q10 in a
pharmaceutically acceptable carrier. The present disclosure further
provides a method to specifically normalize the ratio of
pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family
in a proportion to re-program a cancer cell to undergo
apoptosis.
Inventors: |
Narain; Niven Rajin;
(Cambridge, MA) ; Persaud; Indushekhar;
(Homestead, FL) ; McCook; John Patrick; (Frisco,
TX) |
Assignee: |
Cytotech Labs, LLC
Nashville
TN
|
Family ID: |
41162239 |
Appl. No.: |
13/345570 |
Filed: |
January 6, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12936852 |
Jan 27, 2011 |
|
|
|
PCT/US2009/039992 |
Apr 9, 2009 |
|
|
|
13345570 |
|
|
|
|
61044085 |
Apr 11, 2008 |
|
|
|
Current U.S.
Class: |
435/375 |
Current CPC
Class: |
A61K 9/0014 20130101;
A61K 9/0019 20130101; A61P 43/00 20180101; A61K 9/02 20130101; A61P
35/00 20180101; A61K 9/0048 20130101; A61K 9/06 20130101; A61K 9/12
20130101; A61K 31/122 20130101; A61K 9/127 20130101; A61K 9/0075
20130101 |
Class at
Publication: |
435/375 |
International
Class: |
C12N 5/095 20100101
C12N005/095; A61P 35/00 20060101 A61P035/00; C12N 5/07 20100101
C12N005/07 |
Claims
1. A method comprising: administering to a cell a composition
comprising a liposome comprising a phospholipid and a bioactive
agent comprising coenzyme Q10 or its metabolites; and allowing the
coenzyme Q 10 or its metabolites to form a complex with endogenous
coenzyme Q10 and membrane lipids, wherein the formation of the
complex induces the cell to undergo apoptosis.
2. The method of claim 1, wherein the membrane lipids comprise
endogenous lipids selected from the group consisting of oleic acid,
mevalonic acid and quinones.
3. The method of claim 1, wherein the composition further comprises
a pharmaceutically acceptable carrier, and wherein the coenzyme Q10
is present in an amount of from about 0.001% to about 60% (w/w) of
the composition.
4. The method of claim 1, wherein the composition is in a form
selected from the group consisting of gels, ointments, creams,
salves, lotions, mousses, foams, sprays, aerosols, liquids,
nebulized powders, and suppositories.
5. The method of claim 1, wherein the formation of the complex
induces modulation of a cell protein selected from the group
consisting of p53, Bcl-2, Bcl-2 subfamily members, and Bak.
6. The method of claim 5, wherein modulation of the cell protein
comprises re-activation of the p53 protein.
7. The method of claim 5, wherein modulation of the cell protein
comprises modulating at least one BH3 binding domain of the Bcl-2
family.
8. The method of claim 7, wherein the at least one BH3 binding
domain of the Bcl-2 family is selected from the group consisting of
Bid, Bim, Bik, and combinations thereof.
9. The method of claim 1, wherein the cell is an oncogenic
cell.
10. A method for treating cancer comprising: administering to an
oncogenic cell a composition comprising a liposome comprising a
phospholipid and a bioactive agent comprising coenzyme Q10 or its
metabolites; and allowing the coenzyme Q 10 or its metabolites to
form a complex with endogenous coenzyme Q10 and membrane lipids,
wherein the formation of the complex modulates angiogenic factors
of the oncogenic cell.
11. The method of claim 10, wherein the membrane lipids comprise
endogenous lipids selected from the group consisting of oleic acid,
mevalonic acid and quinones.
12. The method of claim 10, wherein the composition further
comprises a pharmaceutically acceptable carrier, and wherein the
coenzyme Q10 is present in an amount of from about 0.001% to about
60% (w/w) of the composition.
13. The method of claim 10, wherein the composition is in a form
selected from the group consisting of gels, ointments, creams,
salves, lotions, mousses, foams, sprays, aerosols, liquids,
nebulized powders, and suppositories.
14. The method of claim 10, wherein the formation of the complex
modulates angiogenic factors selected from the group consisting of
VEGF, FGF, Hif-1.alpha., and angiostatin.
15. A method for treating cancer comprising: administering to an
oncogenic cell a composition comprising a liposome comprising a
phospholipid and a bioactive agent comprising coenzyme Q10 or its
metabolites; and allowing the coenzyme Q 10 or its metabolites to
form a complex with endogenous coenzyme Q10 and membrane lipids,
wherein the formation of the complex modulates cell-cycle factors
of the oncogenic cell.
16. The method of claim 15, wherein the membrane lipids comprise
endogenous lipids selected from the group consisting of oleic acid,
mevalonic acid and quinones.
17. The method of claim 15, wherein the composition further
comprises a pharmaceutically acceptable carrier, and wherein the
coenzyme Q10 is present in an amount of from about 0.001% to about
60% (w/w) of the composition.
18. The method of claim 15, wherein the composition is in a form
selected from the group consisting of gels, ointments, creams,
salves, lotions, mousses, foams, sprays, aerosols, liquids,
nebulized powders, and suppositories.
19. The method of claim 15, wherein the formation of the complex
modulates cell-cycle factors selected from the group consisting of
smad proteins, TGF-.beta., cyclin-dependent kinases, and PI3K/akt.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U.S.
Provisional Application Ser. No. 61/044,085, filed Apr. 11, 2008,
the entire disclosure of which is incorporated by reference
herein.
BACKGROUND
[0002] Programmed cell death (apoptosis) is integral to the
sustenance of life as the constant renewal of tissue provides the
physiologic scaffold for regenerative metabolism. Apoptosis
facilitates the homeostatic balance of cellular renewal allowing
for overall tissue health, so that the integrity of proliferative,
immunomodulatory, and angiogenic components of tissue metabolism
are maintained. A dysregulation in any one of, or a combination of,
the aforementioned processes may result in a lack of apoptotic
control. Such lack of apoptotic control, optionally in combination
with genetic mutations, may result in a favorable oncogenic
environment.
[0003] Under healthy conditions, the genome's "watchman," p53,
recognizes when a cell's integrity is compromised and commits it to
apoptosis via employment of the Bcl-2 protein family in the
mitochondria leading to nuclear fragmentation. See, e.g.,
Selivanova, et al., "Reactivation of mutant p53: molecular
mechanisms and therapeutic potential," Oncogene (2007) 26,
2243-2254.
[0004] Moreover, the balance of the "pro" and "anti" apoptotic
members of the Bcl-2 protein family may determine the overall
apoptotic potential for a cell. In over 60% of all cancers, p53 is
mutated or inactivated and the Bcl-2 protein is overexpressed,
leading to a resistance to cell death and chemotherapeutic
approaches.
[0005] It has been shown that cancer patients have an overall
decreased serum level of CoQ10 which may lead to sign and symptoms
of malaise, weakness, and lethargy, especially when using
chemotherapeutic modalities. See, e.g., Okamoto, et al. "Serum
levels of coenzyme Q10 and lipids in patients during total
parenteral nutrition," J Nutr Sci Vitaminol (Tokyo), (1986)
February; 32(1):1-12. Studies from the University of Miami using an
athymic mouse model have demonstrated that a liposomal formulation
of CoQ10 reduced human melanoma tumors by 53.2% in 30 days while an
overall attenuation of tumor angiogenesis was observed. See, e.g.,
Persaud, et al., "Attenuation of tumor angiogenesis in murine
melanoma model using liposomal formulation of Coenzyme Q10,"
Proceedings of the American Association for Cancer Research,
(2006); 47:A977. In addition, it was subsequently shown that the
effect of CoQ10 was mediated by a downregulation of the Bcl-2
protein. See, e.g., Narain, et al., "Coenzyme Q10: A novel Bcl-2
drug target for the treatment of melanoma," Proceedings of the
American Association for Cancer Research, (2006); 47:A791.
[0006] Drugs have been developed to target the Bcl-2 protein family
either by direct antibody inhibition or by the use of specific
constructs that interfere with binding, which may lead to
dimerization or oligomerization, in an effort to restore the
balance of the pro- and anti-apoptotic proteins. See, e.g., U.S.
Pat. Nos. 6,514,761 and 6,040,181. However, this does not
fundamentally alter the upstream levels of the major apoptotic
members of the Bcl-2 protein family, such as Bcl-2, Bax, and Bid,
following a re-activation of p53 which enables the given cell to
undergo apoptosis.
SUMMARY
[0007] The present disclosure describes a method of delivering
CoQ10 or its metabolites into a cell and forming a complex with
endogenous CoQ10 and membrane lipids that induces the activation of
p53 and initiation of Bcl-2 mediated apoptosis in a cancer cell by
modulation of the Bcl-2 subfamily members.
[0008] In embodiments, the present disclosure provides a
composition including CoQ10 and phospholipid liposomes that binds
to endogenous lipids that maintain membrane integrity such as oleic
acid in addition to mevalonic acid and quinones. The present
disclosure is also directed to methods of activating p53 and
modulating the expression of the Bcl-2 protein family in a manner
that commits a given cell to undergo apoptosis where that cell is
an oncogenic cell.
[0009] In embodiments, the present disclosure provides a
composition for the treatment of cancer including CoQ10, liposomes,
and a pharmaceutically acceptable carrier. In some embodiments, the
composition includes between about 0.001% to about 60% (w/w) of
Coenzyme Q10.
[0010] In other embodiments, the composition may be in the form of
a gel, ointment, cream, salve, lotion, mousse, foam, spray and/or
aerosol, liquid (intravenous), nebulized powder, suppository, or
any other commercially feasible parenteral route.
[0011] In other embodiments, the present disclosure provides a
method of treating cancer which includes administering to a patient
in need thereof, a composition including a therapeutically
effective amount of CoQ10, liposomes, and a pharmaceutically
acceptable carrier to the area of oncogenesis. In embodiments, the
composition includes between about 0.001% to about 60% (w/w) of
Coenzyme Q10.
[0012] In other embodiments, the present disclosure provides a
method of contacting endogenous CoQ10 by administering to a patient
in need thereof, a composition including a therapeutically
effective amount of CoQ10, liposomes and a pharmaceutically
acceptable carrier to the area of oncogenesis. The composition may
include between about 0.001% to about 60% (w/w) of Coenzyme
Q10.
[0013] The present disclosure also provides a method of targeting
the Bcl-2 family of proteins which includes administering to a
patient in need thereof a composition including a therapeutically
effective amount of CoQ10, liposomes, and a pharmaceutically
acceptable carrier to the area of oncogenesis. In embodiments, the
composition includes between about 0.001% to about 60% (w/w) of
Coenzyme Q10.
[0014] The present disclosure also provides a method of
re-activating the p53 protein which includes administering to a
patient in need thereof a composition including a therapeutically
effective amount of CoQ10, liposomes, and a pharmaceutically
acceptable carrier to the area of oncogenesis. In embodiments, the
composition includes between about 0.001% to about 60% (w/w) of
Coenzyme Q10.
[0015] The present disclosure also provides a method of modulating
the BH3 binding domains of the Bcl-2 family (e.g. Bid, Bim, Bik)
administering to a patient in need thereof, a composition including
a therapeutically effective amount of CoQ10, liposomes and a
pharmaceutically acceptable carrier to the area of oncogenesis. In
embodiments, the composition includes between about 0.001% to about
60% (w/w) of Coenzyme Q10.
[0016] Methods of modulating the Bax protein are also provided
which include, in embodiments, administering to a patient in need
thereof a composition including a therapeutically effective amount
of CoQ10, liposomes and a pharmaceutically acceptable carrier to
the area of oncogenesis. In embodiments, the composition includes
between about 0.001% to about 60% (w/w) of Coenzyme Q10.
[0017] The present disclosure also provides a method of modulating
angiogenic factors such as VEGF, FGF, Hif-1.alpha., and angiostatin
by administering to a patient in need thereof a composition
including a therapeutically effective amount of CoQ10, liposomes
and a pharmaceutically acceptable carrier to the area of
oncogenesis. In embodiments, the composition includes between about
0.001% to about 60% (w/w) of Coenzyme Q10.
[0018] In another embodiment, a method of modulating cell-cycle
factors such as smad proteins, TGF-.beta., cdk's (cyclin-dependent
kinases), and PI3K/akt administering to a patient in need thereof,
a composition including a therapeutically effective amount of
CoQ10, liposomes and a pharmaceutically acceptable carrier to the
area of oncogenesis. In embodiments, the composition includes
between about 0.001% to about 60% (w/w) of Coenzyme Q10.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The above and further advantages of this disclosure may be
better understood by referring to the following description taken
in conjunction with the accompanying drawings, in which:
[0020] FIG. 1 is a depiction of the metabolic synthesis of
CoQ10;
[0021] FIG. 2 is a summary of the interactions of Bax, P53, and
Bcl-2 in the induction of apoptosis;
[0022] FIG. 3 shows Bcl-2 expression in melanoma cells and neonatal
fibroblasts after treatment with 50 .mu.M CoQ10;
[0023] FIG. 4 shows Bcl-2 expression in melanoma cells incubated
with 50 .mu.M and 100 .mu.M CoQ10 for 24 hours;
[0024] FIG. 5 shows Bcl-2 expression in melanoma cells treated in
the presence and absence of CoQ10 using 24 hr Take Away (TA)
method. In TA experiments melanoma cells were treated with CoQ10
for 6, 12, and 24 hours. After incubation the medium was replaced
with normal culture medium for 24 hours. Bcl-2 expression was
measured to assess the commitment to apoptosis;
[0025] FIG. 6 shows Bax expression in melanoma cells after 12 and
24 hours incubation with CoQ10 (50 .mu.M and 100 .mu.M);
[0026] FIG. 7 shows Bax expression in melanoma cells treated in the
presence and absence of CoQ10 using 24 hr Take Away (TA) method. In
TA experiments melanoma cells were treated with CoQ10 for 6, 12,
and 24 hours. After incubation the medium was replaced with normal
culture medium for 24 hours. Bax expression was measured to assess
the commitment to apoptosis;
[0027] FIG. 8 shows Bid expression in melanoma cells after 12 hours
incubation with CoQ10;
[0028] FIG. 9 shows the histopathology analysis of human melanoma
tumors induced in nude athymic mice. The treatment group received a
topical application of CoQ10 for 30 days. Analysis of the tumor
pathology indicates a disruption in tumor vasculature;
[0029] FIGS. 10a-10d show Bcl-2 expression in melanoma cells
incubated with CoQ10 and/or Vascular Endothelial Growth Factor
(VEGF) for 24 hours;
[0030] FIG. 11 shows p53 expression in melanoma cells incubated
with 50 .mu.M and 100 .mu.M CoQ10 for 24 hours;
[0031] FIG. 12 is a graph depicting p53 expression in melanoma
cells incubated with 50 .mu.M and 100 .mu.M CoQ10 for 12 hours;
[0032] FIG. 13 shows Bcl-xl expression in melanoma cells incubated
with CoQ10 for 6 hours;
[0033] FIG. 14 shows Bcl-xl expression in melanoma cells incubated
with CoQ10 for 12 hours;
[0034] FIG. 15 is a graph quantifying Bcl-xl expression in melanoma
cells treated for 12 hours with CoQ10;
[0035] FIG. 16 shows Caspase-3 expression in melanoma cells treated
for 12 hours with CoQ10;
[0036] FIG. 17 is a graph quantifying Caspase-3 expression in
melanoma cells treated for 12 hours with CoQ10;
[0037] FIG. 18 shows Mcl-1 expression in melanoma cells treated
with Coenzyme Q10 for 3, 6, 12, and 24 hours;
[0038] FIG. 19a is a graph quantifying Mcl-1 expression in melanoma
cells incubated with CoQ10 for 12 hours; FIG. 19b is a graph
quantifying Mcl-1 expression in melanoma cells incubated with CoQ10
for 24 hours;
[0039] FIG. 20 is a graph quantifying BAX expression in PC-3
(prostate cancer) cells incubated for 4 hours with CoQ10;
[0040] FIG. 21 is a graph quantifying Bcl-2 expression in PC-3
cells incubated for 4 hours with CoQ10;
[0041] FIG. 22 is a graph showing the time point comparison of
Bcl-2 expression in PC-3 cells treated with CoQ10 for 4 and 24
hours;
[0042] FIG. 23 is a graph quantifying Bcl-2 expression in SkBr-3
(breast cancer) cells incubated for 4 hours with CoQ10;
[0043] FIG. 24 is a graph quantifying Bax expression in SkBr-3
cells incubated for 8 hours with CoQ10;
[0044] FIG. 25 shows Bax expression in SkBr3 cells incubated with
CoQ10 for 8 hours;
[0045] FIG. 26 is a graph comparing Bcl-2 and Bax expression after
24 hours treatment with CoQ10.
DETAILED DESCRIPTION
[0046] The present disclosure provides pharmaceutical compositions
including Coenzyme Q10 (CoQ10) and methods of linking to endogenous
lipid molecules to modulate molecular machinery that relates to an
oncogenic state. The scope of the present disclosure relates to the
fields of molecular medicine and oncology specific to gene
modulation of the p53 pathway and Bcl-2 gene family.
DEFINITIONS
[0047] In accordance with the present disclosure and as used
herein, the following terms are defined with the following
meanings, unless explicitly stated otherwise.
[0048] As used herein, "a", "an," and "the" include plural
references unless the context clearly dictates otherwise.
[0049] As used herein, a "pharmaceutically acceptable" component is
one that is suitable for use with humans and/or animals without
undue adverse side effects (such as toxicity, irritation, and
allergic response) commensurate with a reasonable benefit/risk
ratio.
[0050] As used herein, the term "safe and therapeutic effective
amount" refers to the quantity of a component which is sufficient
to yield a desired therapeutic response without undue adverse side
effects (such as toxicity, irritation, or allergic response)
commensurate with a reasonable benefit/risk ratio when used in the
manner of this disclosure. By "therapeutically effective amount" is
meant an amount of a compound of the present disclosure effective
to yield the desired therapeutic response. For example, accelerate
wound healing, relief of pain and fatigue. The specific safe and
effective amount or therapeutically effective amount will vary with
such factors as the particular condition being treated, the
physical condition of the patient, the type of mammal or animal
being treated, the duration of the treatment, the nature of
concurrent therapy (if any), and the specific formulations employed
and the structure of the compounds or its derivatives.
[0051] As used herein, a "pharmaceutical salt" include, but are not
limited to, mineral or organic acid salts of basic residues such as
amines; alkali or organic salts of acidic residues such as
carboxylic acids. Suitable salts may be made using an organic or
inorganic acid. Such salts include chlorides, bromides, sulfates,
nitrates, phosphates, sulfonates, formates, tartrates, maleates,
malates, citrates, benzoates, salicylates, ascorbates, and the
like. In embodiments, hydrochloride salt may be utilized.
[0052] "Diagnostic" or "diagnosed" means identifying the presence
or nature of a pathologic condition. Diagnostic methods differ in
their sensitivity and specificity. The "sensitivity" of a
diagnostic assay is the percentage of diseased individuals who test
positive (percent of "true positives"). Diseased individuals not
detected by the assay are "false negatives." Subjects who are not
diseased and who test negative in the assay, are termed "true
negatives." The "specificity" of a diagnostic assay is 1 minus the
false positive rate, where the "false positive" rate is defined as
the proportion of those without the disease who test positive.
While a particular diagnostic method may not provide a definitive
diagnosis of a condition, it suffices if the method provides a
positive indication that aids in diagnosis.
[0053] The terms "patient" or "individual" are used interchangeably
herein, and refers to a mammalian subject to be treated, with human
patients being suitable in some embodiments. In some cases, the
methods of the present disclosure find use in experimental animals,
in veterinary application, and in the development of animal models
for disease, including, but not limited to, rodents including mice,
rats, and hamsters; and primates.
[0054] "Sample" is used herein in its broadest sense. A sample
including polynucleotides, polypeptides, peptides, antibodies and
the like may include a bodily fluid; a soluble fraction of a cell
preparation, or media in which cells were grown; a chromosome, an
organelle, or membrane isolated or extracted from a cell; genomic
DNA, RNA, or cDNA, polypeptides, or peptides in solution or bound
to a substrate; a cell; a tissue; a tissue print; a fingerprint,
skin or hair; and the like.
[0055] "Treatment" is an intervention performed with the intention
of preventing the development or altering the pathology or symptoms
of a disorder. Accordingly, "treatment" refers to both therapeutic
treatment and prophylactic or preventative measures. Those in need
of treatment include those already with the disorder as well as
those in which the disorder is to be prevented. As used herein,
"ameliorated" or "treatment" refers to a symptom which is
approaches a normalized value (for example a value obtained in a
healthy patient or individual), e.g., is less than 50% different
from a normalized value, in embodiments less than about 25%
different from a normalized value, in other embodiments is less
than 10% different from a normalized value, and in yet other
embodiments the presence of a symptom is not significantly
different from a normalized value as determined using routine
statistical tests.
[0056] As used herein, "an ameliorated symptom" or "treated
symptom" refers to a symptom which is approaches a normalized
value, e.g., is less than 50% different from a normalized value, in
embodiments less than about 25% different from a normalized value,
in other embodiments less than about 10% different from a
normalized value, and yet other embodiments the presence of a
symptom is not significantly different from a normalized value as
determined using routine statistical tests.
Subjects
[0057] Subjects from many different species can be treated with the
compositions of the present disclosure. A non-exhaustive exemplary
list of such animals includes mammals such as mice, rats, rabbits,
goats, sheep, pigs, horses, cattle, dogs, cats, and primates such
as monkeys, apes, and human beings. Those animal subjects known to
suffer muscle fatigue, pain, wounds, and the like may be suitable
for use in the present disclosure. In particular, human patients
suffering from injuries, surgery, arthritis, muscle fatigue and the
like are suitable animal subjects for use in the present
disclosure. By adapting the methods taught herein to other methods
known in medicine or veterinary science (e.g., adjusting doses of
administered substances according to the weight of the subject
animal), the compositions utilized in the present disclosure can be
readily optimized for use in other animals.
Pharmaceutical Compositions and Administration to a Subject
[0058] In embodiments, the present disclosure provides CoQ10
compositions for the treatment and prevention of cancer.
Transdermal, oral intravenous, and other parenteral preparations of
2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone (coenzyme
Q-10) may include, inter alia, auxiliary agents, an effective
amount of pulmonary surfactant, and/or in combination with
liposomes.
[0059] In embodiments, the compositions including CoQ10 may be
administered topically. It may be desirable to present the active
ingredient, e.g. CoQ10, as a pharmaceutical formulation. Exemplary
compositions are described in detail in the examples which follow.
The active ingredient may include, for topical administration, from
0.001% to about 60% w/w, by weight of the formulation in the final
product, although it may include as much as 80% w/w, in embodiments
from about 0.001% to about 60% w/w of the formulation. The topical
formulations of the present disclosure, include an active
ingredient together with one or more acceptable carrier(s) thereof
and optionally any other therapeutic ingredients(s). The carrier(s)
must be "acceptable" in the sense of being compatible with the
other ingredients of the formulation and not deleterious to the
recipient thereof.
[0060] In some embodiments, the CoQ10 may be included in a
composition such as the composition disclosed in U.S. patent
application Ser. No. 12/052,825, the entire disclosure of which is
incorporated by reference herein.
[0061] The composition of the present disclosure can be
administered to a patient either by themselves, or in
pharmaceutical compositions where it is mixed with suitable
carriers or excipient(s). In treating a patient exhibiting a
disorder of interest, a therapeutically effective amount of an
agent or agents such as these is administered. A therapeutically
effective dose refers to that amount of the compound that results
in amelioration of symptoms or a prolongation of survival in a
patient.
[0062] Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the LD.sub.50 (the
dose lethal to 50% of the population) and the ED.sub.50 (the dose
therapeutically effective in 50% of the population). The dose ratio
between toxic and therapeutic effects is the therapeutic index and
it can be expressed as the ratio LD.sub.50/ED.sub.50. Compounds
which exhibit large therapeutic indices may be desirable. The data
obtained from these cell culture assays and animal studies can be
used in formulating a range of dosage for use in human. The dosage
of such compounds may be within a range of circulating
concentrations that include the ED.sub.50 with little or no
toxicity. The dosage may vary within this range depending upon the
dosage form employed and the route of administration utilized.
[0063] For any compound used in the method of the present
disclosure, the therapeutically effective dose can be estimated
initially from cell culture assays. For example, a dose can be
formulated in animal models to achieve a circulating plasma
concentration range that includes the IC.sub.50 as determined in
cell culture. Such information can be used to more accurately
determine useful doses in humans. Levels in plasma may be measured,
for example, by HPLC.
[0064] The exact formulation, route of administration and dosage
can be chosen by the individual physician in view of the patient's
condition. (See e.g. Fingl et al., in The Pharmacological Basis of
Therapeutics, 1975, Ch. 1 p. 1). It should be noted that the
attending physician would know how to and when to terminate,
interrupt, or adjust administration due to toxicity, or to organ
dysfunctions. Conversely, the attending physician would also know
to adjust treatment to higher levels if the clinical response were
not adequate (precluding toxicity). The magnitude of an
administrated dose in the management of the oncogenic disorder of
interest will vary with the severity of the condition to be treated
and to the route of administration. The severity of the condition
may, for example, be evaluated, in part, by standard prognostic
evaluation methods. Further, the dose and perhaps dose frequency,
will also vary according to the age, body weight, and response of
the individual patient. A program comparable to that discussed
above for humans may be used in veterinary medicine.
[0065] The compositions of the present disclosure can be applied to
a patient by treatment modalities that are tailored to the patient,
such as the type of injury, severity of the injury, location of the
injury. For example, the percentage of the active composition can
be modulated during the course of treatment again depending on
severity, type of injury etc. CoQ10 the active ingredient, may
include, from 0.001% to about 60% w/w, by weight of the formulation
in the final product, although it may include as much as 80% w/w,
in embodiments from about 0.001% to about 60% w/w of the
formulation.
[0066] The compositions can be applied to a patient at least once a
day. In other embodiments the pharmaceutical compositions can be
applied, twice a day, three times a day or more. The times and
compositions containing the active ingredients can easily be
determined by a clinician.
[0067] Depending on the specific conditions being treated, such
agents may be formulated and administered systemically or locally.
Techniques for formulation and administration may be found in
Remington's Pharmaceutical Sciences, 18.sup.th ed., Mack Publishing
Co., Easton, Pa. (1990). Suitable routes may include oral, rectal,
transdermal, vaginal, transmucosal, or intestinal administration;
parenteral delivery, including intramuscular, subcutaneous,
intramedullary injections, as well as intrathecal, direct
intraventricular, intravenous, intraperitoneal, intranasal, or
intraocular injections, just to name a few.
[0068] The compositions described above may be administered to a
subject in any suitable formulation. In addition to treatment of
cancer with topical formulations of CoQ10, in other aspects of the
present disclosure CoQ10 might be delivered by other methods. For
example, CoQ10 might be formulated for parenteral delivery, e.g.,
for subcutaneous, intravenous, intramuscular, or intratumoral
injection. Other methods of delivery, for example, liposomal
delivery or diffusion from a device impregnated with the
composition might be used. The compositions may be administered in
a single bolus, multiple injections, or by continuous infusion (for
example, intravenously or by peritoneal dialysis). For parenteral
administration, the compositions may be formulated in a sterilized
pyrogen-free form. Compositions of the present disclosure can also
be administered in vitro to a cell (for example, to Bcl-2
production in a cell or in an in vitro culture) by simply adding
the composition to the fluid in which the cell is contained.
[0069] Depending on the specific conditions being treated, such
agents may be formulated and administered systemically or locally.
Techniques for formulation and administration may be found in
Remington's Pharmaceutical Sciences, 18.sup.th ed., Mack Publishing
Co., Easton, Pa. (1990). Suitable routes may include oral, rectal,
transdermal, vaginal, transmucosal, or intestinal administration;
parenteral delivery, including intramuscular, subcutaneous,
intramedullary injections, as well as intrathecal, direct
intraventricular, intravenous, intraperitoneal, intranasal, or
intraocular injections, just to name a few.
[0070] For injection, the agents of the present disclosure may be
formulated in aqueous solutions, for example, in physiologically
compatible buffers such as Hanks' solution, Ringer's solution, or
physiological saline buffer. For such transmucosal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the
art.
[0071] Use of pharmaceutically acceptable carriers to formulate the
compounds herein disclosed for the practice of the present
disclosure into dosages suitable for systemic administration is
within the scope of the present disclosure. With proper choice of
carrier and suitable manufacturing practice, the compositions of
the present disclosure, in particular, those formulated as
solutions, may be administered parenterally, such as by intravenous
injection. The compounds can be formulated readily using
pharmaceutically acceptable carriers well known in the art into
dosages suitable for oral administration. Such carriers enable the
compounds of the present disclosure to be formulated as tablets,
pills, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient to be treated.
[0072] Agents intended to be administered intracellularly may be
administered using techniques well known to those of ordinary skill
in the art. For example, such agents may be encapsulated into
liposomes, then administered as described above. Liposomes are
spherical lipid bilayers with aqueous interiors. All molecules
present in an aqueous solution at the time of liposome formation
are incorporated into the aqueous interior. The liposomal contents
are both protected from the external microenvironment and, because
liposomes fuse with cell membranes, are efficiently delivered into
the cell cytoplasm. Additionally, due to their hydrophobicity,
small organic molecules may be directly administered
intracellularly.
[0073] Pharmaceutical compositions suitable for use in the present
disclosure include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
Determination of the effective amounts is well within the
capability of those skilled in the art, especially in light of the
detailed disclosure provided herein. In addition to the active
ingredients, these pharmaceutical compositions may contain suitable
pharmaceutically acceptable carriers including excipients and
auxiliaries which facilitate processing of the active compounds
into preparations which can be used pharmaceutically. The
preparations formulated for oral administration may be in the form
of tablets, dragees, capsules, or solutions. The pharmaceutical
compositions of the present disclosure may be manufactured in a
manner that is itself known, e.g., by means of conventional mixing,
dissolving, granulating, dragee-making, levitating, emulsifying,
encapsulating, entrapping or lyophilizing processes.
[0074] Formulations suitable for topical administration include
liquid or semi-liquid preparations suitable for penetration through
the skin to the site of where treatment is required, such as
liniments, lotions, creams, ointments or pastes, and drops suitable
for administration to the eye, ear, or nose. Drops according to the
present disclosure may include sterile aqueous or oily solutions or
suspensions and may be prepared by dissolving the active ingredient
in a suitable aqueous solution of a bactericidal and/or fungicidal
agent and/or any other suitable preservative, and in some
embodiments including a surface active agent. The resulting
solution may then be clarified and sterilized by filtration and
transferred to the container by an aseptic technique. Examples of
bactericidal and fungicidal agents suitable for inclusion in the
drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium
chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable
solvents for the preparation of an oily solution include glycerol,
diluted alcohol and propylene glycol.
[0075] Lotions according to the present disclosure include those
suitable for application to the skin or eye. An eye lotion may
include a sterile aqueous solution optionally containing a
bactericide and may be prepared by methods similar to those for the
preparation of drops. Lotions or liniments for application to the
skin may also include an agent to hasten drying and to cool the
skin, such as an alcohol or acetone, and/or a moisturizer such as
glycerol or an oil such as castor oil or arachis oil.
[0076] Creams, ointments or pastes according to the present
disclosure are semi-solid formulations of the active ingredient for
external application. They may be made by mixing the active
ingredient in finely-divided or powdered form, alone or in solution
or suspension in an aqueous or non-aqueous fluid, with the aid of
suitable machinery, with a greasy or non-greasy basis. The basis
may include hydrocarbons such as hard, soft or liquid paraffin,
glycerol, beeswax, a metallic soap; a mucilage; an oil of natural
origin such as almond, corn, arachis, castor or olive oil; wool fat
or its derivatives, or a fatty acid such as stearic or oleic acid
together with an alcohol such as propylene glycol or macrogels. The
formulation may incorporate any suitable surface active agent such
as an anionic, cationic or non-ionic surface active such as
sorbitan esters or polyoxyethylene derivatives thereof. Suspending
agents such as natural gums, cellulose derivatives or inorganic
materials such as silicaceous silicas, and other ingredients such
as lanolin, may also be included.
[0077] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions.
[0078] Pharmaceutical preparations for oral use can be obtained by
combining the active compounds with solid excipient, optionally
grinding a resulting mixture, and processing the mixture of
granules, after adding suitable auxiliaries, if desired, to obtain
tablets or dragee cores. Suitable excipients are, in particular,
fillers such as sugars, including lactose, sucrose, mannitol, or
sorbitol; cellulose preparations such as, for example, maize
starch, wheat starch, rice starch, potato starch, gelatin, gum
tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxy-methylcellulose, and/or polyvinyl pyrrolidone (PVP). If
desired, disintegrating agents may be added, such as the
cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt
thereof such as sodium alginate.
[0079] Dragee cores are provided with suitable coating. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0080] Pharmaceutical preparations which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added.
[0081] The composition can include a buffer system, if desired.
Buffer systems are chosen to maintain or buffer the pH of
compositions within a desired range. The term "buffer system" or
"buffer" as used herein refers to a solute agent or agents which,
when in a water solution, stabilize such solution against a major
change in pH (or hydrogen ion concentration or activity) when acids
or bases are added thereto. Solute agent or agents which are thus
responsible for a resistance or change in pH from a starting
buffered pH value in the range indicated above are well known.
While there are countless suitable buffers, potassium phosphate
monohydrate may be a suitable buffer.
[0082] The final pH value of the pharmaceutical composition may
vary within the physiological compatible range. The final pH value
should not be irritating to human skin and may also be selected so
that transdermal transport of the active compound, e.g. CoQ10, may
be facilitated. Without violating this constraint, the pH may be
selected to improve CoQ10 compound stability and to adjust
consistency when required. In one embodiment, the pH value may be
from about 3 to about 7.4, in embodiments from about 3.2 to about
6.5, in other embodiments from about 3.5 to about 6.
[0083] In some embodiments, the remaining component of a topical
delivery vehicle may be water, in embodiments purified, e.g.
deionized, water. Such delivery vehicle compositions may contain
water in an amount of from about 50 to about 95 percent, based on
the total weight of the composition. The specific amount of water
present is not critical, however, being adjustable to obtain the
desired viscosity (usually about 50 cps to about 10,000 cps) and/or
concentration of the other components. The topical delivery vehicle
may have a viscosity of at least about 30 centipoises.
[0084] Other known transdermal skin penetration enhancers can also
be used to facilitate delivery of CoQ10. Illustrative are
sulfoxides such as dimethylsulfoxide (DMSO) and the like; cyclic
amides such as 1-dodecylazacycloheptane-2-one (AZONE.RTM., a
registered trademark of Nelson Research, Inc.) and the like; amides
such as N,N-dimethyl acetamide (DMA) N,N-diethyl toluamide,
N,N-dimethyl formamide, N,N-dimethyl octamide, N,N-dimethyl
decamide, and the like; pyrrolidone derivatives such as
N-methyl-2-pyrrolidone, 2-pyrrolidone, 2-pyrrolidone-5-carboxylic
acid, N-(2-hydroxyethyl)-2-pyrrolidone or fatty acid esters
thereof, 1-lauryl-4-methoxycarbonyl-2-pyrrolidone, N-tallow
alkylpyrrolidones, and the like; polyols such as propylene glycol,
ethylene glycol, polyethylene glycol, dipropylene glycol, glycerol,
hexanetriol, and the like; linear and branched fatty acids such as
oleic, linoleic, lauric, valeric, heptanoic, caproic, myristic,
isovaleric, neopentanoic, trimethyl hexanoic, isostearic, and the
like; alcohols such as ethanol, propanol, butanol, octanol, oleyl,
stearyl, linoleyl, and the like; anionic surfactants such as sodium
laurate, sodium lauryl sulfate, and the like; cationic surfactants
such as benzalkonium chloride, dodecyltrimethylammonium chloride,
cetyltrimethylammonium bromide, and the like; non-ionic surfactants
such as the propoxylated polyoxyethylene ethers, e.g., Poloxamer
231, Poloxamer 182, Poloxamer 184, and the like, the ethoxylated
fatty acids, e.g., Tween 20, Myrj 45, and the like, the sorbitan
derivatives, e.g., Tween 40, Tween 60, Tween 80, Span 60, and the
like, the ethoxylated alcohols, e.g., polyoxyethylene (4) lauryl
ether (Brij 30), polyoxyethylene (2) oleyl ether (Brij 93), and the
like, lecithin and lecithin derivatives, and the like; the terpenes
such as D-limonene, .alpha.-pinene, .beta.-carene,
.alpha.-terpineol, carvol, carvone, menthone, limonene oxide,
.alpha.-pinene oxide, eucalyptus oil, and the like.
[0085] Also suitable as skin penetration enhancers are organic
acids and esters such as salicylic acid, methyl salicylate, citric
acid, succinic acid, and the like.
Effective Amounts
[0086] The compositions described above may be administered to a
subject in an effective amount. An effective amount is an amount
which is capable of producing a desirable result in a treated
animal or cell. As is well known in the medical and veterinary
arts, dosage for any one animal depends on many factors, including
the particular animal's size, body surface area, age, the
particular composition to be administered, time and route of
administration, general health, and other drugs being administered
concurrently. It is expected that an appropriate dosage for topical
administration of the compositions of the present disclosure would
be from about 0.1 to about 2.5 mg CoQ10/kg of body weight (e.g.,
from about 10 to about 500 mg for subjects ranging from about 110
to about 300 lbs. An effective amount for use with a cell in
culture will also vary, but can be readily determined empirically
(for example, by adding varying concentrations to the cell and
selecting the concentration that best produces the desired result).
It is expected that an appropriate concentration would be from
about 1 to about 250 .mu.M.
EXAMPLES
[0087] Materials utilized for the experiments to generate the data
accompanying the present disclosure included the following:
Skmel-28 (HTB-72), PC-3 (CRL-1435), and SkBr3 (HBT-30) were
purchased from ATCC. The cell lines were grown in DMEM/F12 medium
(Dulbecco's Modified Eagle Medium:Nutrient Mixture F-12,
commercially available from Invitrogen Corporation) and
supplemented with 5% bovine calf serum. The Bcl-2 (Cat #:2872), Bax
(Cat#:2774), Bid (Cat#:2002), p53 (Cat#:9282), Bcl-xl (Cat#:2762),
Caspase-3 (Cat#:9662), Mcl-1 (Cat#:4572), Bax (Cat#:2772),
Anti-rabbit IgG (Cat#:7074), and Anti-Mouse IgG (Cat#:7076)
antibodies were purchased from Cell Signaling Technology (Boston,
Mass.). Reagents and chemicals were purchased from Sigma Aldrich
(St Louis, Mo.). Western blot gels and buffers were purchased from
Bio-Rad (Hercules, Calif.).
Example 1
[0088] Protein Expression Protocol. (Generated the Data Found in
FIGS. 3, 4, 5, 6, 7, 10a-10d, 13, 14, 16, 18, 19a, and 25.)
[0089] Skmel-28, PC-3, and SkBr3 cells were grown to 80% confluency
and subcultured in petri dishes. After 24 hours, the cells adhered
to the plates and the medium was extracted. Treatment medium was
added to each plate. Following the intended incubation time, the
medium was removed and the cells were washed with cold phosphate
buffered saline (PBS). The cells were scraped in cold PBS and
collected in centrifuge tubes. Cells were then pelleted and washed
with cold PBS (3 times). The PBS was removed, after which a lysis
buffer was added and sonicated to disperse the protein structures.
A sample buffer was added to each tube and the solutions were
boiled for 5 minutes. Using a BCA (bicinchoninic acid) protein
analysis kit, the concentration of protein was quantified for each
sample. These values determined the loading volumes for each
samples.
[0090] The samples were loaded in a 4% stacking and 12% running
Tris-Hcl gel western blot gels. After separation, the bands of
protein were transferred to nitrocellulose paper using
electrophoresis. The nitrocellulose paper was blocked overnight
with 5% milk solutions. The respective antibodies were added to
each nitrocellulose paper containing the protein samples. After 24
hours the primary antibody was removed and the extraction paper was
washed to remove any unbounded primary antibodies. Depending on the
type of the primary antibody, an anti-mouse or anti-rabbit
secondary antibody was added to the protein extracts. After
incubation, the antibodies were removed and the nitrocellulose
papers were washed. A Pico Chemo-luminescent was added and the
nitrocellulose paper was exposed to X-Ray development film under
dark room conditions. The film was developed to record the protein
expression.
Graphical Analysis for the Western Blot Analysis (Generated the
Data Found in FIGS. 12, 15, 17, 19a, 20, 21, 22, 23, 24, 26.)
[0091] The procedure for protein expression was used to obtain a
photographic image of the protein expression. These imaged were
scanned into image files for computer analysis. Using ImageJ
software developed by the U.S. National Institutes of Health (NIH),
the levels of protein expression were quantified. The expression
was then calculated based on the level of expression of the actin,
which was the loading control for the samples. The numerical values
were statistically analyzed for statistical significance.
Histological Samples
[0092] Skmel-28 cells were grown in 5% serum-supplemented DMEM/F12
medium to 80% confluency. The cells were trypsinized and pelleted
using a centrifuge. The pellets were then resuspended in cold PBS.
The subjects for this study were nude athymic mice. Each subject
received two injections of the cell suspension on the dorsal region
of the mouse. After a visual assessment of the establishment of a
tumor, treatment with a topical application would commence. After
30 days of treatment, the tumors were excised from the mice and
placed in formalin. Each tumor sample was embedded in paraffin and
sliced using a microtome. The slides underwent an H & E or
S-100 stain. These samples were then analyzed by a pathologist to
assess the vascular integrity of the tumor.
[0093] The Figures provide details regarding the synthesis of
CoQ10, and the interactions of endogenous proteins in a cancer
state, including their expression in cancer states. The Figures
also depict the data obtained from the above experiments, and
demonstrate the effects the administration of a compound such as
CoQ10, in varying concentrations and for varying periods of time,
had on various types of cancer cells. Briefly, in summary, the
Figures include the following:
[0094] FIG. 1 is a depiction of the metabolic synthesis of
CoQ10;
[0095] FIG. 2 is a summary of the interactions of Bax, P53, and
Bcl-2 in the induction of apoptosis;
[0096] FIG. 3 shows Bcl-2 expression in melanoma cells and neonatal
fibroblasts after treatment with 50 .mu.M CoQ10;
[0097] FIG. 4 shows Bcl-2 expression in melanoma cells incubated
with 50 .mu.M and 100 .mu.M CoQ10 for 24 hours;
[0098] FIG. 5 shows Bcl-2 expression in melanoma cells treated in
the presence and absence of CoQ10 using a 24 hour Take Away (TA)
method. In TA experiments, melanoma cells were treated with CoQ10
for 6, 12, and 24 hours. After incubation the medium was replaced
with normal culture medium for 24 hours. Bcl-2 expression was
measured to assess the commitment to apoptosis;
[0099] FIG. 6 shows Bax expression in melanoma cells after 12 and
24 hours incubation with CoQ10 (50 .mu.M and 100 .mu.M);
[0100] FIG. 7 shows Bax expression in melanoma cells treated in the
presence and absence of CoQ10 using 24 hr Take Away (TA) method. In
TA experiments melanoma cells were treated with CoQ10 for 6, 12,
and 24 hours. After incubation the medium was replaced with normal
culture medium for 24 hours. Bax expression was measured to assess
the commitment to apoptosis;
[0101] FIG. 8 shows Bid expression in melanoma cells after 12 hours
incubation with CoQ10;
[0102] FIG. 9 shows the histopathology analysis of human melanoma
tumors induced in nude athymic mice. The treatment group received a
topical application of CoQ10 for 30 days. Analysis of the tumor
pathology indicates a disruption in tumor vasculature;
[0103] FIGS. 10a-10d show Bcl-2 expression in melanoma cells
incubated with CoQ10 and/or Vascular Endothelial Growth Factor
(VEGF) for 24 hours;
[0104] FIG. 11 shows p53 expression in melanoma cells incubated
with 50 .mu.M and 100 .mu.M CoQ10 for 24 hours;
[0105] FIG. 12 is a graph depicting p53 expression in melanoma
cells incubated with 50 .mu.M and 100 .mu.M CoQ10 for 12 hours;
[0106] FIG. 13 shows Bcl-xl expression in melanoma cells incubated
with CoQ10 for 6 hours;
[0107] FIG. 14 shows Bcl-xl expression in melanoma cells incubated
with CoQ10 for 12 hours;
[0108] FIG. 15 is a graph quantifying Bcl-xl expression in melanoma
cells treated for 12 hours with CoQ10;
[0109] FIG. 16 shows Caspase-3 expression in melanoma cells treated
for 12 hours with CoQ10;
[0110] FIG. 17 is a graph quantifying Caspase-3 expression in
melanoma cells treated for 12 hours with CoQ10;
[0111] FIG. 18 shows Mcl-1 expression in melanoma cells treated
with Coenzyme Q10 for 3, 6, 12, and 24 hours;
[0112] FIG. 19a is a graph quantifying Mcl-1 expression in melanoma
cells incubated with CoQ10 for 12 hours; FIG. 19b is a graph
quantifying Mcl-1 expression in melanoma cells incubated with CoQ10
for 24 hours;
[0113] FIG. 20 is a graph quantifying BAX expression in PC-3
(prostate cancer) cells incubated for 4 hours with CoQ10;
[0114] FIG. 21 is a graph quantifying Bcl-2 expression in PC-3
cells incubated for 4 hours with CoQ10;
[0115] FIG. 22 is a graph showing the time point comparison of
Bcl-2 expression in PC-3 cells treated with CoQ10 for 4 and 24
hours;
[0116] FIG. 23 is a graph quantifying Bcl-2 expression in SkBr-3
(breast cancer) cells incubated for 4 hours with CoQ10;
[0117] FIG. 24 is a graph quantifying Bax expression in SkBr-3
cells incubated for 8 hours with CoQ10;
[0118] FIG. 25 shows Bax expression in SkBr3 cells incubated with
CoQ10 for 8 hours;
[0119] FIG. 26 is a graph comparing Bcl-2 and Bax expression after
24 hours treatment with CoQ10.
Conditions/Disorders/Uses
[0120] As noted above, compositions of the present disclosure may
be utilized for the treatment of cancer. Such compositions may
include CoQ10 or its metabolites in a pharmaceutically acceptable
carrier. Such a composition may effectuate cell contact of
endogenous Coenzyme Q10 or its metabolites thereof in addition to,
but not limited to, mevalonic acid and oleic acid to form an
intracellular complex. In embodiments, such a composition may
include from about 0.001% to about 60% (w/w) of Coenzyme Q10. Such
compositions may be topical compositions which, in turn, may be
gels, ointments, liquids, creams, salves, lotions, sprays,
aerosols, mousses, foams, combinations thereof, and the like.
[0121] As also noted above, compositions of the present disclosure
may be in a liquid form, capable of introduction into a subject by
any means or route of administration within the purview of those
skilled in the art. For example, compositions may be administered
by routes of administration including, but not limited to, the
lungs, intravenous, oral, transdermal, rectal, subcutaneous,
transmucosal, buccal, sublingual, intratumoral, combinations
thereof, and the like.
[0122] In some embodiments, it may be desirable to nebulize or
aerosolize the compositions for administration.
[0123] Methods for treating disease states with the compositions
herein are also provided. Such methods may include treating cancer.
Where utilized to treat cancer, the compositions may be in a
pharmaceutically acceptable carrier that may be administered in a
therapeutically effective amount to an area of oncogenesis as
either a monotherapy, in combination with at least one other
chemotherapeutic agent for a given indication, in combination with
radiotherapy, following surgical intervention to radically remove a
tumor, in combination with other alternative and/or complementary
acceptable treatments for cancer, and the like.
[0124] In embodiments, the present disclosure also provides a
method claim for re-activating a mutated/inactivated p53 protein by
administering to an area of oncogenesis in a patient a composition
of the present disclosure.
[0125] The present disclosure also provides methods for modulating
proteins implicated in oncogenesis by administering to an area of
oncogenesis in a patient a composition of the present disclosure.
Such proteins which may be modulated by compositions of the present
disclosure include, but are not limited to: Bcl-2 protein; Bax
protein; Bid protein; Bim protein; Bad protein; Bak protein; mcl-1
protein; Bcl-xl protein; Bcl-xs protein; Bcl-w protein; Bik
protein; Bok protein; BimL protein; A1 protein; Hrk protein; Bik
protein; BNIP3 protein; Blk protein; Noxa protein; Puma protein;
VEGF protein; FGF-1/FGF-2 protein; Hif-.alpha. protein; angiostatin
protein; TGF-.beta. protein; smad proteins; cdk (cyclin-dependent
kinases); the PI3K/akt complex.
[0126] In other embodiments, compositions of the present disclosure
may be utilized to regulate and/or restore a healthy apoptosis
state in cancer cells. Mitochondrial dysfunction and dysregulation
of apoptosis are implicated in many diseases such as cancer and
neurodegeneration. Respiratory chain (RC) dysfunction may have a
role in apoptosis, as demonstrated using mitochondrial DNA
mutations as genetic models. Although some mutations eliminate the
entire RC, others target specific complexes, resulting in either
decreased or complete loss of electron flux, which leads to
impaired respiration and adenosine triphosphate (ATP) synthesis.
Despite these similarities, significant differences in responses to
apoptotic stimuli emerge. Cells lacking RC are protected against
both mitochondrial- and endoplasmic reticulum (ER) stress-induced
apoptosis. Cells with RC, but unable to generate electron flux, are
protected against mitochondrial apoptosis, although they have
increased sensitivity to ER stress. Finally, cells with a partial
reduction in electron flux have increased apoptosis under both
conditions. RC modulates apoptosis in a context-dependent manner
independent of ATP production and that apoptotic responses are the
result of the interplay between mitochondrial functional state and
environmental cues.
[0127] The execution of apoptosis and communication between
oncogenic factors may also be mediated by released factors such as
cytochrome C, Endo G, or AIF through mitochondrial membrane pores
which open upon membrane depolarization.
[0128] Cancer cells also generate excessive lactate in the presence
of oxygen (aerobic glycolysis). It now appears that this phenomenon
is the product of two factors: a return to the more glycolytic
metabolism of the embryo and alterations in oxidative
phosphorylation (OXPHOS) to increase mitochondrial reactive oxygen
species (ROS) production. Alterations in the Ras-PI3K-Akt signal
transduction pathway can result in induction of hexokinase II and
its attachment to mitochondrial porin redirecting mitochondrial ATP
to phosphorylate glucose and drive glycolysis. Furthermore, partial
inhibition of OXPHOS by mitochondrial gene mutations (germ-line or
somatic) can reduce electron flux through the electron transport
chain, increasing mitochondrial ROS production. The increased ROS
mutagenizes nuclear proto-oncogenes (initiation) and drives nuclear
replication (promotion), resulting in cancer. Therefore, hexokinase
II and mitochondrial ROS may be useful alternate targets for cancer
therapeutics.
[0129] Metabolic flux as it relates to cancer is compromised in an
oncogenic state and shifts towards a glycolytic state. A cancer
cell's survival is vitally dependent on glucose metabolism and low
oxygen levels. More perplexing is that mitochondrial activity is
significantly attenuated to the point of dormancy. Oxidative
phosphorylation usually associated with Complex I-IV that accepts
electrons from the Citric Acid Cycle (TCA) is essentially shut
down. There is a marked increase in the amount of free radicals and
lactate dehydrogenase activity. Hence, the cancer cell is in state
of:
[0130] 1) Decreased oxygen (Hypoxia)
[0131] 2) Increase free-radical formation
[0132] 3) Dysregulated apoptosis (cell death)
[0133] 4) Dependence of glucose metabolism
[0134] 5) Increased blood vessel formation
[0135] 6) Altered immune recognition (auto-regulatory state
commences)
[0136] In embodiments, the effect CoQ10 may have on cancer cells
may depend, in part, on the various states of metabolic and
oxidative flux exhibited by the cancer cells. CoQ10 may be utilized
to interrupt and/or interfere with the conversion of an oncogenic
cell's dependency of glycolysis and increased lactate utility. As
it relates to a cancer state, this interference with the glycolytic
and oxidative flux of the tumor microenvironment may influence
apoptosis and angiogenesis in a manner which reduces the
development of a cancer cell.
[0137] In embodiments, the interaction of Coenzyme Q10 with
glycolytic and oxidative flux factors may enhance the ability of
Coenzyme Q10 to exert its restorative apoptotic effect in cancer
while establishing viable drug targets for drug discovery and
development.
[0138] While the above disclosure has focused on Coenzyme Q10 and
its metabolites, other compounds related to CoQ10 which may be
administered instead of, or in combination with, CoQ10 include, but
are not limited to, benzoquinones, isoprenoids, farnesols, farnesyl
acetate, farnesyl pyrophosphate, l-phenylalanine, d-phenylalanine,
dl-phenylalanine, l-tyrosine, d-tyrosine, dl-tyrosine,
4-hydroxy-phenylpyruvate, 4-hydroxy-phenyllactate,
4-hydroxy-cinnamate, dipeptides and tripeptides of tyrosine or
phenylalanine, 3,4-dihydroxymandelate,
3-methoxy-4-hydroxyphenylglycol, 3-methoxy-4-hydroxymandelate,
vanillic acid, phenylacetate, pyridoxine, S-adenosyl methionine,
panthenol, mevalonic acid, isopentyl pyrophosphate, phenylbutyrate,
4-hydroxy-benzoate, decaprenyl pyrophosphate, beta-hydroxybutyrate,
3-hydroxy-3-methyl-glutarate, acetylcarnitine,
acetoacetylcarnitine, acetylglycine, acetoacetylglycine, carnitine,
acetic acid, pyruvic acid, 3-hydroxy-3-methylglutarylcarnitine, all
isomeric forms of serine, alanine, cysteine, glycine, threonine,
hydroxyproline, lysine, isoleucine, and leucine, even carbon number
C4 to C18 fatty acids (butyric, caproic, caprylic, capric, lauric,
myristic, palmitic, and stearic acids) salts of carnitine and
glycine, e.g., palmitoylcarnitine and palmitoylglycine, and
4-hydroxy-benzoate polyprenyltransferase, any salts of these
compounds, as well as any combinations thereof, and the like.
[0139] The figures are offered by way of illustration, not by way
of limitation. While specific examples have been provided, the
above description is illustrative and not restrictive. Any one or
more of the features of the previously described embodiments can be
combined in any manner with one or more features of any other
embodiments in the present disclosure. Furthermore, many variations
of the present disclosure will become apparent to those skilled in
the art upon review of the specification.
Other References
[0140] All publications and patent documents cited in this
application are incorporated by reference in pertinent part for all
purposes to the same extent as if each individual publication or
patent document were so individually denoted. By their citation of
various references in this document, Applicants do not admit any
particular reference is "prior art" to their disclosure.
[0141] It is to be understood that while the present disclosure has
been described in conjunction with the detailed description
thereof, the foregoing description is intended to illustrate and
not limit the scope of the present disclosure, which is defined by
the scope of the appended claims. Other aspects, advantages, and
modifications are within the scope of the following claims and
their equivalents.
* * * * *